EverSource Wealth Advisors’s BridgeBio Pharma BBIO Stock Holding History

EverSource Wealth Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33.7K	Sell	453 -228	-33%	-$16K	﹤0.01%	2048
2026 Q1	$50.6K	Buy	681 +149	+28%	+$10.8K	﹤0.01%	1872
2025 Q4	$40.7K	Buy	532 +74	+16%	+$4.86K	﹤0.01%	1890
2025 Q3	$23.8K	Sell	458 -14	-3%	-$683	﹤0.01%	2241
2025 Q2	$20.4K	Buy	472 +244	+107%	+$8.88K	﹤0.01%	2270
2025 Q1	$7.88K	Buy	228 +64	+39%	+$2.16K	﹤0.01%	2252
2024 Q4	$4.5K	Buy	164 +97	+145%	+$2.51K	﹤0.01%	2396
2024 Q3	$1.71K	Sell	67 -10	-13%	-$263	﹤0.01%	2588
2024 Q2	$2K	Hold	77	–	–	﹤0.01%	2547
2024 Q1	$1.97K	Sell	77 -78	-50%	-$2.65K	﹤0.01%	2389
2023 Q4	$6.26K	Buy	+155	New	+$4.66K	﹤0.01%	1766
2022 Q2	–	Sell	-109	Closed	-$1K	–	1715
2022 Q1	$1K	Hold	109	–	–	﹤0.01%	1630
2021 Q4	$2K	Buy	+109	New	+$4.61K	﹤0.01%	1504

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

EverSource Wealth Advisors's BBIO Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its BridgeBio Pharma (BBIO) stake by 33% in Q2 2026, selling an estimated $16K and leaving 453 shares worth $33.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2048.

EverSource Wealth Advisors first reported a position in BBIO in Q4 2021 and has held it in 13 quarters since. The position peaked at $50.6K in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

EverSource Wealth Advisors held 453 shares of BridgeBio Pharma worth $33.7K as of Q2 2026.
EverSource Wealth Advisors sold 228 BridgeBio Pharma shares in Q2 2026, an estimated $16K.
BridgeBio Pharma made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #2048 holding.
EverSource Wealth Advisors first reported a position in BridgeBio Pharma in Q4 2021 and has held it in 13 quarters since.
EverSource Wealth Advisors's BridgeBio Pharma position peaked at $50.6K in Q1 2026.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.